ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$87.49
−0.73%Next report
Analyst consensus
- Next report date
- Dec 21, 2026
- EPS estimate
- -$1.27
- Revenue estimate
- $771.4K
Latest reported
- Last report date
- Sep 21, 2026
- EPS actual
- -$1.71
- EPS estimate
- -$1.03
- Revenue actual
- $1.4M
- Revenue estimate
- $799.2K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -6.6%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $149
- PT range
- $118 – $175
- Analysts
- 6
5 Buy1 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 21, 2026 | -$1.03 | -$1.71 | Miss -66.07% | $1.4M |
| May 22, 2026 | -$0.94 | -$0.71 | Beat 24.12% | $1.5M |
| Mar 23, 2026 | -$1.35 | -$1.20 | Beat 11.00% | $509.4K |
| Sep 8, 2025 | -$0.90 | -$0.86 | Beat 4.44% | $2.4M |
| Mar 24, 2025 | -$0.68 | -$1.55 | Miss -128.04% | $7.7M |
| Nov 7, 2024 | -$1.28 | -$0.70 | Beat 45.50% | $3.6M |
| Apr 2, 2024 | -$0.91 | -$1.94 | Miss -112.73% | $2.6M |
| Jun 29, 2019 | — | -$1.57 | — | — |
| Dec 31, 2018 | — | -$0.98 | — | $386.0K |
| Jun 30, 2018 | — | -$0.84 | — | $571.1K |
| Dec 31, 2017 | — | -$0.66 | — | $413.0K |
| Jun 30, 2017 | — | -$0.65 | — | $4.6K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 21, 2026